ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is making headlines with the sudden announcement of the CEO’s retirement and an application delay for the company’s leading drug.
In a research report issued today, Needham analyst Alan Carr reiterated a Buy rating on Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) and reduced the price target to …
In a research report issued today, Needham analyst Alan Carr reiterated a Buy rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a $40 price target, after …
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological …
H.C.
J.P.
In a research report published this morning, Needham analyst Alan Carr maintained a Buy rating on Acadia (NASDAQ:ACAD) and raised his price target …
